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Introduction
Approximately 100 million adults undergo non-cardiac surgery worldwide every year 1 and up to 40% of these patients have or are at risk of coronary artery disease (CAD). 2 Four million patients have been estimated to have a major perioperative cardiovascular complication, including cardiac death, nonfatal myocardial infarction and cardiac arrest per year. 2 Furthermore, data show that perioperative myocardial infarction (PMI) is associated with an in-hospital mortality of 15-25%. [3] [4] [5] With a high prevalence of CAD, the appropriate perioperative management of high-risk patients treated with aspirin is a common clinical problem for the attending surgeon and anaesthetist.
Aspirin has been used for decades in secondary prevention of myocardial infarction or stroke in patients with ischaemic heart or cerebro-vascular disease and its efficacy has been well documented. The 2002 Antithrombotic Trialists' Collaboration reported that antiplatelet therapy reduced the risk of non-fatal myocardial infarction by one-third, non-fatal stroke by one-fourth and vascular events by one-sixth. Aspirin is therefore strongly recommended as a life-long therapy after coronary or cerebro-vascular event. 6 Despite evidence to the benefit of antiplatelet therapy in patients at risk of cardiac and cerebro-vascular complications, aspirin treatment is often discontinued prior to surgery due to the risk of perioperative bleeding. [7] [8] [9] Thus, the question whether to continue or discontinue aspirin in the perioperative period remains unanswered. This study was therefore undertaken with the primary aim of assessing the incidence of perioperative myocardial damage in patients with or without low-dose aspirin treatment in the perioperative period. Our hypothesis was that low-dose aspirin reduces the incidence of myocardial damage and MACE (defined as acute myocardial infarction, severe arrhythmia, cardiac arrest or cardiovascular death) without increasing bleeding complications.
Methods
All Regional ethics committees approved the protocol for this randomized, double blind, placebo-controlled multi-center study (ASINC-Aspirin in non-cardiac surgery, Eudract CT number 2004-005136-76) and the study complied with the Declaration of Helsinki.
Patients
Patients undergoing elective, high or intermediate risk non-cardiac surgery 10 between
November 2005 and December 2008 and having at least one of the following cardiac risk factors were eligible for inclusion: ischaemic heart disease (angina pectoris or previous myocardial infarction), congestive heart failure (previous diagnosis of heart failure), renal intracoronary stent were excluded from the study.
Study design
After giving written informed consent, the patients were randomly assigned to receive either 75 mg aspirin or placebo using a computer-generated algorithm. The study product, as well as reference product, both of identical shape, weight and appearance, was provided by Apoteket 11 . In the event of myocardial damage in the preoperative period, the attending anaesthetist, cardiologist and surgeon together evaluated the risk/benefit of the surgical procedure and surgery was rescheduled when appropriate. If a myocardial infarction was diagnosed, the study medication was terminated and aspirin therapy started. The anaesthetic and surgical techniques used were not defined in the protocol, but left to the judgment of the attending physicians.
Perioperative events, including haemodynamic instability (systolic blood pressure ± 30% of baseline), hypoxaemia (SpO 2 < 90% for > 5 min), new arrhythmia, tachycardia (heart rate + 30 beats minutes -1 from baseline for > 5 minutes) or bradycardia (heart rate < 45 for > 5 minutes) were documented. In addition, perioperative blood loss, fluid requirements, packed red blood cells, plasma and platelet transfusions were recorded. The attending surgeon made a subjective assessment of intraoperative bleeding by using an ordinal scale from 1 to 5, where 1 was normal surgical bleeding and 5 was greatly increased surgical bleeding. Reoperations due to bleeding complications as well as major bleeding from other organs including epidural or intracranial haematoma, cerebro-vascular complications and death within 30 days were also recorded.
Study endpoints
Postoperative myocardial damage, as defined earlier, was considered to be the primary endpoint. 
Follow-up
Telephone interviews were conducted 30 days after surgery. In addition, computer-based medical records were assessed. Information about new cardiovascular complications, readmissions and transfers to high dependency units were documented. Excessive perioperative bleeding was also documented. If a patient died during the follow-up period, information on the cause of death was obtained from medical records, death certificates and autopsy reports. The cause of death was classified as cardiovascular, malignancy or other.
Statistical analysis
The statistical analyses were done on an intention-to-treat principle. In case of missing data (data not entered in case report files or in computer-based medical records), patients were assumed not to have had an event. Sample size was calculated on the basis of two previous studies. In the first study, low dose aspirin had been shown to decrease the risk of myocardial infarction by 50%. 12 In the second study, 14% of a subgroup of patients with similar inclusion criteria as patients in the present study had an elevated TnT in the postoperative period. 13 Based on these data, we calculated that the inclusion of 540 patients would be required to detect a 50% reduction in the number of patients with myocardial damage (as defined earlier) with a statistical power of 80% and an α level of 0.05.
An independent multidisciplinary data management & safety board planned an interim analysis after 100 included patients. The trial was to be stopped if there was a significant difference (p<0.01) between the groups in either the number of patients with myocardial damage or the occurrence of major bleeding between the groups. No significant differences were detected between the groups at the interim analysis and therefore the study was continued as planned. No other interim analyses were planned or performed during the study period.
Numerical variables were tested for normal distribution and are presented as mean ± SD or median (interquartile range). For analyses of continuous data τ-test or Mann-Whitney U test were used as appropriate, to detect differences between the groups. Dichotomous variables are described as numbers and percentage and were analyzed by using χ 2 test or Fisher's exact test as appropriate. Absolute and relative risk ratios for cardiovascular complications were calculated and presented with their 95% confidence intervals. In addition, numbers needed to treat was calculated. The level of statistical significance was specified as p ≤0.05, (twotailed). All analyses were performed using STATA v10.1 (Stata Corp LP; College Station, Tx, USA).
Results
Of the planned 540 patients, the study was terminated in December 2008 after inclusion of 220 patients at the seven centers. The study was stopped prior to full enrollment, without statistical analysis, for a number of reasons. The main reason was that during the study period, new recommendations on high-risk patients taking aspirin were published recommending a continuation of aspirin in the perioperative period. 7, [14] [15] [16] Many of our investigators were therefore reluctant to continue randomizing high-risk patients into this study. Another reason for terminating the study was that we had difficulty in finding eligible patients for inclusion, especially after the amendment in 2006 that required exclusion of patients with intracoronary stents. Finally, we estimated that if recruitment of patients continued at the present rate, it would take at least another five years before the study was completed, a period of time during which the continuing rapid changes in patient management by physicians would make it increasingly difficult to recruit patients and would delay dissemination of applicable information gained by this study.
Of the 220 patients included in the study, one hundred and nine patients received aspirin and 111 patients received placebo. In seven of the randomized patients, surgery was postponed, while ten patients did not comply with the treatment, Figure 1 . All these patients were included in the statistical analyses. Patient characteristics, concomitant medication and comorbidities are described in Table 1 . There were no significant differences between the groups in these variables.
Myocardial Damage
Fourteen patients (6.4%) had a TnT ≥0.04µg•L -1 on at least one occasion in the first 48 hours postoperatively. Ten patients (9.0%) in the placebo group and four patients (3.7%) in the aspirin group had postoperative elevated TnT levels, (p=0.10). Five patients had elevated TnT prior to surgery, Table 1 . Three of these patients were treated with aspirin and two with placebo (p=0.60). One patient was transferred to a coronary care unit, and surgery was postponed. In one patient, surgery was delayed for further cardiac investigation. In the remaining three cases, surgery and anaesthesia were undertaken without any delay and intraoperative management was left to the attending anaesthetist. Thirty-nine patients that were included had a percutaneous coronary intervention in their medical history. Twenty-two of these patients received aspirin and 17 had placebo during the study period. One patient in the placebo group developed a TnT elevation in the postoperative period.
Other events
Twelve patients (13%) in the placebo group developed myocardial ischaemia on the ECG in the postoperative period, compared to11 patient (11%) in the aspirin group, (p= 0.83).
Tachycardia was seen significantly more often in the placebo group compared to patients treated with aspirin, eight patients in the placebo group (7%) compared to none in the ASA group, Table 2 . Only one of the patients with tachycardia developed a MACE. In contrast, patients in the aspirin group had more frequent episodes of bradycardia, (p=0.02). All data are presented as n (%) unless otherwise stated. Tachycardia: an increase in heart rate of > 30 for > 5 minutes. Bradycardia: heart rate < 45 for > 5 min Hypo-/ hypertension: ± 30% of baseline systolic blood pressure. Hypoxaemia: SpO 2 <90% for > 5 minutes. Patients were assumed not to have had a complication in case of missing data.
Major Adverse Cardiac Events & Mortality
Twelve patients (6 %) had a major adverse cardiac event, including myocardial infarction, severe arrhythmia, cardiac arrest or cardiovascular death within 30 days of surgery, Table 3 .
Ten of these patients (9.0%) were in the placebo group and 2 patients (1.8%) were in the aspirin group, (p =0.02), Table 3 . Treatment with aspirin resulted in an absolute risk reduction of 7.2% (95% CI 1.3-13) and a relative risk reduction of 80% (95% CI 9.2-95%) for postoperative cardiovascular events within the first 30 days after surgery. Numbers needed to treat was 14 (95% CI 7.6-78).
None of the patients with preoperative elevated TnT had a MACE in the first 30 postoperative days. There was no MACE in the subgroup of patients that had undergone percutaneous coronary intervention. A majority of patients having MACE had it early in the postoperative period. One patient (1.1%) in the aspirin group and 8 patients in the placebo group (8.2%) had MACE within the first three postoperative days, p=0.02.
Thirteen patients had cerebro-vascular events (MACE and TIA/stroke) in the postoperative period. Ten of these patients were in the placebo group (9%) and three (2.7%) in the aspirin group, p=0.049.
In patients on chronic low-dose acetylsalicylic acid treatment prior to the study (n=196; 90% of the study population), 10 patients (10%) who were randomized to receive placebo developed a MACE compared to 1 patient (2%) receiving acetylsalicylic acid during the study period, p= 0.03.
Four patients (2%) died within 30 days of the surgical procedure (n = 2 in each group). The cause of death in these patients was classified as cardiovascular in one patient. The remaining three causes of death were classified as other.
Bleeding complications
Two patients (2%) in the aspirin group but none in the placebo group had bleeding which required reoperation in the perioperative period (p=0.24), Table 4 . Both these patients underwent prostatic surgery, one transurethral resection of the prostate and the other open prostatectomy for benign prostatic hypertrophy. During the study period, a total of five adverse events due to bleeding were documented (3 in the aspirin group and 2 in the placebo group). These events included bruising or greater per-operative bleeding than expected. No significant differences in the amount of per-or postoperative bleeding were seen between patients who were treated with aspirin compared to patients who were treated with placebo.
The surgeon's assessment of peroperative bleeding tendency did not show any significant differences between the groups, Table 4 . No statistically significant differences were detected in the amount of crystalloids, packed red blood cells -or plasma transfusions between the groups. However, patients in the placebo group received more colloids than those in the aspirin group (p=0.02). 
Discussion
In this prospective randomized placebo-controlled multi-center study, we found that treatment with low-dose aspirin in the perioperative period reduced the relative risk of major adverse cardiac events within 30 days of surgery by 80% (absolute risk-reduction 7.2%). A trend was also seen towards a reduction in myocardial damage postoperatively. However, this trend did not reach statistical significance. In addition, we found that there were no significant differences between the groups in perioperative bleeding including severe haemorrhage, amount of perioperative bleeding, packed red blood cells and plasma transfusions or the surgeon's assessment of the operative bleeding tendency.
Aspirin reduces platelet aggregation for the lifespan of the platelet, approximately 8-10 days. 17 Numerous publications on major morbidity and mortality have shown the efficacy of lowdose aspirin in secondary prevention of cardiovascular events 6, 18, 19 and aspirin should therefore be continued throughout life in patients at-risk. 19, 20 Recent data on the risk of discontinuing anti-platelet therapy in patients with coronary stents has highlighted the use of aspirin in the perioperative period. [21] [22] [23] As a result, the routine withdrawal of aspirin 7-10 days prior to surgery has been questioned and some recent publications recommend that aspirin should not be stopped routinely in the perioperative period. 14, 15, 24, 25 However, these recommendations were not based on evidence from controlled trials elucidating the risk/benefit of aspirin in the setting of non-cardiac surgery. Indeed, prospective, randomized studies on this important problem are singularly lacking in the literature. Therefore, there are two important issues that need to be discussed. Firstly, does stopping aspirin perioperatively cause any harm to patients who are at risk of a cardiovascular complication? Secondly, does continuing aspirin result in any significant increase in perioperative bleeding?
One of the problems with aspirin withdrawal is the risk of a rebound phenomenon. Abrupt cessation of aspirin results in an increase in thromboxane A2 activity and a decrease in fibrinolysis, resulting in increased platelet adhesion and aggregation. 26, 27 In addition, the surgical trauma by itself creates a prothrombotic and proinflammatory state, including platelet activation/aggregation and reduced fibrinolytic activity. 28, 29 One meta-analysis of the literature found that aspirin withdrawal was associated with a significantly increased risk of myocardial infarction and death. 27 We found, in the present study, that there was a statistically significant increase in the incidence of MACE within 30 days after surgery when aspirin was stopped as opposed to its continuation in the perioperative period. Since a vast majority of our patients were taking aspirin preoperatively (90%), it is impossible to be certain whether the effects seen were a consequence of aspirin treatment or aspirin withdrawal in patients already on antiplatelet therapy. There was a higher incidence of episodes of postoperative tachycardia in patients taking placebo compared to patients receiving acetylsalicylic acid. However, only one of these eight patients developed a MACE, and therefore episodes of tachycardia alone cannot explain the higher incidence of MACE in the placebo group.
The incidence of myocardial damage was not significantly different between the groups. This could be due to the small number of patients recruited into this study but could also be due to several other factors including: a) the small number of patients undergoing high-risk surgery (<20%) with a high revised cardiac risk index (< 10%), b) all patients did not have ischaemic heart disease and c) patients who had insulin-dependent diabetes mellitus without other evidence of coronary artery disease were included into this study. It is possible that the results of myocardial damage would have been different if we had only included patients with ischaemic heart disease or cerebro-vascular disease where aspirin has the greatest benefit.
The next issue is whether continuing aspirin perioperatively increases the risk of bleeding?
The mechanism of action of aspirin is well known and the decrease in platelet aggregation when using aspirin can lead to an increased risk of bleeding, even when used in low doses. A meta-analysis of 474 studies showed that the use of aspirin increased intraoperative bleeding by a factor of 1.5. 7 However, no increased risk in morbidity or mortality was found in this systematic review. In our present study, two patients in the aspirin group required to be reoperated due to bleeding. Both these patients underwent prostatic surgery (transurethral prostatectomy and open prostatectomy). There has been some concern amongst urologists about continuing aspirin perioperatively and a previous meta-analysis of studies did suggest a higher risk in patients undergoing urological surgery. 7 In the present study there was no evidence of an increase in perioperative bleeding, packed red blood cells/plasma transfusions or the surgeon's assessment of the operative bleeding tendency in the aspirin group compared to patients taking placebo. The overall incidence of perioperative bleeding was low and there were no statistical differences between the groups. However, we have to emphasize that this study was not designed to assess the differences in bleeding complications between the groups. Therefore future studies that are designed to assess bleeding complications with continuing aspirin treatment, should specifically assess patients undergoing prostatectomy in order to detect potential risk of perioperative bleeding. We would like to stress that this study was not designed to detect differences in bleeding complications between the groups and therefore it is underpowered to detect these differences.
Study Limitations
There are some limitations to the results of our study. First and foremost, the study was stopped before the intended 540 patients were included. The main reasons for discontinuing the study are described under results.
Since our study is underpowered, it is more difficult to draw definite conclusions on the consequences of our findings. For example, we could not substantiate that aspirin reduced the risk of myocardial damage, which was our primary endpoint, although there was a clear trend towards this. However, we did establish that aspirin therapy did not increase perioperative morbidity or mortality. Therefore, since little harm was shown in continuing aspirin therapy perioperatively, and a trend towards improved outcome was evident, we believe that our study adds to the previous evidence from non-controlled trials that aspirin should be continued perioperatively in high-risk patients.
In conclusion, we found a statistically significant reduction in MACE within 30 days of surgery in patients treated with aspirin compared to patients given placebo. No significant increase in haemorrhagic complications was observed in patients treated with aspirin. The relatively small number of patients recruited, limits our conclusions and larger studies may need to be performed in order to confirm our findings. 
